Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vir Biotechnology, Inc. Director's Dealing 2021

Oct 20, 2021

32538_dirs_2021-10-20_4e768537-7289-42fa-a22e-1b037ad91a69.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2021-10-19

Reporting Person: SATO VICKI L (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-10-19 Common Stock S 6671 $39.1206 Disposed 1589943 Direct
2021-10-19 Common Stock S 8503 $39.9083 Disposed 1581440 Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.57 to $39.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.